Company Overview - Full Name: Shanghai Yinuosi Biotechnology Co., Ltd [1] - Abbreviation: Yinuosi [1] - Stock Code: 688710.SH [1] - IPO Application Date: December 29, 2022 [1] - Listing Date: September 3, 2024 [1] - Listing Board: Shanghai Stock Exchange Sci-Tech Innovation Board [1] - Industry: Research and Experimental Development [1] - IPO Sponsor: Haitong Securities [1] - Lead Underwriters: Haitong Securities [1] - Legal Advisor: Guohao Law Firm (Shanghai) [1] - Audit Firm: Lixin Certified Public Accountants (Special General Partnership) [1] Disclosure and Evaluation - Disclosure Issues: The actual controller, China National Pharmaceutical Group, has inconsistencies in the main business of its subsidiary related to the issuer, requiring clarification on the completeness of similar business entities [1] - Regulatory Penalties: No penalties [2] - Public Supervision: No penalties [2] - Listing Cycle: Yinuosi's listing cycle is 614 days, shorter than the average of 629.45 days for A-share companies in 2024 [2] - Multiple Applications: Yinuosi is not categorized as having multiple applications [2] Financial Metrics - Issuance Costs: The underwriting and sponsorship fees amount to 44.4235 million yuan, with a commission rate of 6.61%, lower than the average of 7.71% [3] - First Day Performance: The stock price increased by 41.61% on the first day of listing [3] - Three-Month Performance: The stock price rose by 108.39% within three months of listing [4] - Issuance Price-Earnings Ratio: The issuance P/E ratio is 15.40 times, which is 83.83% of the industry average of 18.37 times [5] - Actual Fundraising: Expected fundraising is 1.664 billion yuan, but actual fundraising is only 672 million yuan, a decrease of 59.63% [6] Short-term Performance - Revenue Growth: In 2024, the company's revenue increased by 9.94% year-on-year [7] - Net Profit Decline: The net profit attributable to the parent company decreased by 24.00% year-on-year, and the non-recurring net profit dropped by 28.12% year-on-year [7] - Abandonment Rate: The abandonment rate is 0.23% [7] Overall Score - Total Score: Yinuosi's IPO project received a total score of 86, classified as B-level [7] - Negative Factors: The score is impacted by the need for improved disclosure quality, significant reduction in actual fundraising, decline in net profit in the first accounting year, and the abandonment rate of 0.23% [7]

两融数据显示，该股最新（9月18日）两融余额为7728.90万元，其中，融资余额为7728.90万元，近10日 减少1307.17万元，环比下降14.47%。 机构评级来看，近10日共有1家机构对该股进行评级，9月12日东方证券发布的研报给予公司目标价为 43.24元。 公司发布的半年报数据显示，上半年公司共实现营业收入3.75亿元，同比下降38.04%，实现净利 润-1518.95万元，同比下降115.88%，基本每股收益为-0.1100元。（数据宝）注：本文系新闻报道，不 构成投资建议，股市有风险，投资需谨慎。 （原标题：益诺思创历史新高，融资客减仓） 益诺思股价创出历史新高，截至10:09，该股上涨7.66%，股价报49.78元，成交量157.01万股，成交金额 7555.59万元，换手率1.73%，该股最新A股总市值达70.18亿元，该股A股流通市值45.15亿元。 证券时报•数据宝统计显示，益诺思所属的医药生物行业，目前整体跌幅为0.77%，行业内，目前股价上 涨的有60只，涨幅居前的有益诺思、首药控股、百诚医药等，涨幅分别为7.66%、5.20%、4.61%。股价 下跌的有428只，跌幅居前的有塞 ...

Market Overview - On September 17, the medical services sector rose by 0.02% compared to the previous trading day, with Yinos leading the gains [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Top Gainers in Medical Services Sector - Yinos (688710) closed at 46.85, with an increase of 8.65% and a trading volume of 46,200 lots, amounting to a transaction value of 207 million [1] - New Mileage (002219) closed at 2.49, up 4.18%, with a trading volume of 2,568,500 lots and a transaction value of 638 million [1] - Prasis (301257) closed at 50.33, increasing by 3.52% with a trading volume of 50,700 lots, totaling 249 million [1] Top Losers in Medical Services Sector - Medisi (688202) closed at 76.00, down 5.41%, with a trading volume of 91,400 lots and a transaction value of 700 million [2] - Yaoshi Technology (300725) closed at 44.74, decreasing by 5.11%, with a trading volume of 262,900 lots and a transaction value of 1.18 billion [2] - Zhaoyan New Drug (603127) closed at 40.40, down 4.27%, with a trading volume of 444,300 lots and a transaction value of 1.806 billion [2] Fund Flow Analysis - On the same day, the medical services sector experienced a net outflow of 626 million from institutional investors, while retail investors saw a net inflow of 482 million [2] - The top stocks by net inflow from institutional investors included Yinos (688710) with a net inflow of 26.06 million, and New Mileage (002219) with 38.30 million [3] - Conversely, the top stocks with net outflow from institutional investors included Yao Ming Kande (603259) with a net outflow of 428 million [3]

嘉实医药健康股票A（005303）基金经理为孙晓晖、郝淼。 截至发稿，孙晓晖累计任职时间160天，现任基金资产总规模9.85亿元，任职期间最佳基金回报 41.81%， 任职期间最差基金回报41.31%。 郝淼累计任职时间6年246天，现任基金资产总规模36.52亿元，任职期间最佳基金回报183.83%， 任职 期间最差基金回报-27.96%。 9月17日，益诺思涨5.01%，截至发稿，报45.28元/股，成交1.21亿元，换手率3.06%，总市值63.84亿 元。益诺思股价已经连续5天上涨，区间累计涨幅14.8%。 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自由贸易试验区郭守敬路199号106室，成 立日期2010年5月12日，上市日期2024年9月3日，公司主营业务涉及专业提供生物医药非临床研究服务 为主的综合研发服务(CRO)。主营业务收入构成为：非临床96.31%，临床3.42%，其他0.27%。 从益诺思十大流通股东角度 数据显示，嘉实基金旗下1只基金位居益诺思十大流通股东。嘉实医药健康股票A（005303）二季度新 进十大流通股东，持有股数34.43万股，占流通股的比例为1.22%。根 ...

Core Viewpoint - Yinos's stock price has shown significant growth this year, with a notable increase in recent trading days, indicating positive market sentiment towards the company [2]. Group 1: Stock Performance - Yinos's stock price increased by 25.04% year-to-date, with a 13.11% rise in the last five trading days, 5.09% in the last 20 days, and 36.90% over the last 60 days [2]. - As of September 17, Yinos's stock was trading at 44.00 CNY per share, with a market capitalization of 6.203 billion CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yinos reported a revenue of 375 million CNY, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million CNY, down 115.88% year-on-year [2]. - Cumulative cash dividends paid by Yinos since its A-share listing amount to 45.1135 million CNY [3]. Group 3: Shareholder Information - As of June 30, 2025, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, with an average of 5,235 circulating shares per shareholder, an increase of 0.91% [2]. - Notable changes in institutional holdings include ICBC Medical Health Stock becoming the seventh largest shareholder, increasing its holdings by 72,300 shares, while new shareholders include ICBC Strategic Transformation Stock and Harvest Medical Health Stock [3].

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

证券代码：688710 证券简称：益诺思 公告编号：2025-033 上海益诺思生物技术股份有限公司 关于变更公司网址及投资者邮箱的公告 董事会 2025年9月13日 上海益诺思生物技术股份有限公司（以下简称"公司"）为进一步提升公司品牌形象，经公司研究决定， 对公司官方网址及企业邮箱域名进行变更。现将具体相关情况公告如下： ■ 变更后的公司官方网址及投资者邮箱将于2025年9月15日起正式启用，为保障访问与沟通顺畅，过渡期 为2025年9月15日至2026年3月15日，过渡期内访问原官方网址将自动跳转至新网址，原投资者邮箱信件 将同步至新投资者邮箱，确保信息传递不受影响。除上述变更外，公司投资者联系电话、传真、联系地 址保持不变，敬请留意。欢迎广大投资者通过上述渠道与公司交流沟通。 特此公告！ 上海益诺思生物技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ...

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议资料目录 | 2025年第三次临时股东大会须知 | | 3 | | --- | --- | --- | | 2025年第三次临时股东大会会议议程 | | 5 | | 议案一：关于续聘会计师事务所的议案 | | 6 | | 议案二：关于购买董监高责任险的议案 | | 7 | 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会 会议资料 二〇二五年九月 七、股东发言由大会主持人组织，股东发言时应先报告所持股票数量和持 股人名称。股东在股东大会上的发言，应围绕本次大会所审议的议案，简明扼 要，时间原则上不超过 5 分钟，经主持人同意后方可延长发言时间。主持人可 安排公司董事、监事和其他高级管理人员等回答股东问题，与本次股东大会议 题无关或涉及国家秘密、公司商业秘密或可能损害公司、股东利益的问题，大 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会会议资料 2025年第三次临时股东大会须知 根据中国证券监督管理委员会《上市公司股东大会规则》和《公 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-033 上海益诺思生物技术股份有限公司 关于变更公司网址及投资者邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海益诺思生物技术股份有限公司董事会 2025年9月13日 上海益诺思生物技术股份有限公司（以下简称"公司"）为进一步提升公司 品牌形象，经公司研究决定，对公司官方网址及企业邮箱域名进行变更。现将具 体相关情况公告如下： | 变更内容 | 变更前 | 变更后 | | --- | --- | --- | | 公司官方网址 | www.innostar.cn | www.innostarbio.com | | 投资者邮箱 | bo@innostar.cn | bo@innostarbio.com | 变更后的公司官方网址及投资者邮箱将于2025年9月15日起正式启用，为保 障访问与沟通顺畅，过渡期为2025年9月15日至2026年3月15日，过渡期内访问原 官方网址将自动跳转至新网址，原投资者邮箱信件将同步至新投资者邮箱，确保 信息传递不受影响 ...

Company Overview - Yinos Bio is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company went public on September 3, 2024. Its main business involves providing non-clinical research services in the biopharmaceutical sector, primarily as a Contract Research Organization (CRO) [1] - The revenue composition of Yinos Bio is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Financial Performance - As of June 30, 2025, Yinos Bio reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%. The net profit attributable to shareholders was -15.19 million yuan, representing a year-on-year decrease of 115.88% [2] - Since its A-share listing, Yinos Bio has distributed a total of 45.11 million yuan in dividends [3] Stock Performance - On September 12, Yinos Bio's stock price increased by 2.02%, reaching 39.98 yuan per share, with a trading volume of 46.57 million yuan and a turnover rate of 1.31%. The total market capitalization is 5.636 billion yuan [1] - Year-to-date, Yinos Bio's stock price has risen by 13.61%. However, it has seen a decline of 0.10% over the last five trading days and an 8.89% decrease over the last 20 days, while it has increased by 27.94% over the last 60 days [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Yinos Bio was 5,386, a decrease of 0.90% from the previous period. The average number of circulating shares per person increased by 0.91% to 5,235 shares [2] - Among the top ten circulating shareholders, ICBC Medical Health Stock (000831) is the seventh largest with 439,400 shares, an increase of 72,300 shares from the previous period. New entrants include ICBC Strategic Transformation Stock A (000991) and Harvest Medical Health Stock A (005303) [3]